Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroblastoma | 145 | 2024 | 1263 | 11.900 |
Why?
|
Oncogene Proteins | 33 | 2015 | 710 | 1.660 |
Why?
|
L-Lactate Dehydrogenase | 6 | 2020 | 412 | 1.360 |
Why?
|
Bone Marrow Neoplasms | 4 | 2020 | 101 | 1.290 |
Why?
|
Gene Amplification | 29 | 2022 | 1091 | 1.250 |
Why?
|
Infant | 133 | 2024 | 36386 | 1.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 52 | 2024 | 11868 | 1.080 |
Why?
|
Ganglioneuroma | 4 | 2020 | 53 | 1.010 |
Why?
|
Child, Preschool | 122 | 2024 | 42500 | 0.950 |
Why?
|
Disease-Free Survival | 61 | 2023 | 6832 | 0.940 |
Why?
|
Nuclear Proteins | 36 | 2019 | 5783 | 0.870 |
Why?
|
Ganglioneuroblastoma | 4 | 2018 | 10 | 0.860 |
Why?
|
Hematopoietic Stem Cell Transplantation | 20 | 2024 | 5753 | 0.840 |
Why?
|
Child | 146 | 2024 | 80564 | 0.800 |
Why?
|
Pyruvate Kinase | 5 | 2021 | 192 | 0.720 |
Why?
|
Prognosis | 66 | 2024 | 29922 | 0.710 |
Why?
|
Ferritins | 5 | 2021 | 600 | 0.670 |
Why?
|
Neoplasm Staging | 53 | 2024 | 11206 | 0.650 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 2023 | 891 | 0.640 |
Why?
|
Pyruvate Metabolism, Inborn Errors | 4 | 2021 | 50 | 0.630 |
Why?
|
Nomograms | 1 | 2020 | 235 | 0.620 |
Why?
|
Anemia, Hemolytic, Congenital Nonspherocytic | 4 | 2021 | 56 | 0.620 |
Why?
|
Topotecan | 5 | 2011 | 130 | 0.570 |
Why?
|
Bayes Theorem | 1 | 2024 | 2354 | 0.530 |
Why?
|
Information Dissemination | 2 | 2024 | 1142 | 0.530 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2023 | 9373 | 0.520 |
Why?
|
Adolescent | 99 | 2024 | 88835 | 0.510 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 6 | 2018 | 266 | 0.490 |
Why?
|
Information Storage and Retrieval | 1 | 2021 | 834 | 0.480 |
Why?
|
Molecular Targeted Therapy | 4 | 2024 | 2822 | 0.480 |
Why?
|
Cyclophosphamide | 13 | 2023 | 2228 | 0.480 |
Why?
|
Interleukin-2 | 6 | 2022 | 1896 | 0.460 |
Why?
|
Isotretinoin | 6 | 2021 | 135 | 0.450 |
Why?
|
Graft vs Host Disease | 7 | 2024 | 3078 | 0.450 |
Why?
|
Age Factors | 22 | 2024 | 18380 | 0.430 |
Why?
|
Neoplasms, Second Primary | 5 | 2023 | 1050 | 0.430 |
Why?
|
Humans | 240 | 2024 | 765968 | 0.420 |
Why?
|
Survival Rate | 36 | 2024 | 12795 | 0.400 |
Why?
|
Databases, Factual | 5 | 2024 | 8067 | 0.400 |
Why?
|
Neoplasm Proteins | 4 | 2020 | 3596 | 0.380 |
Why?
|
Survival Analysis | 31 | 2021 | 10070 | 0.380 |
Why?
|
Proto-Oncogene Proteins c-myc | 6 | 2016 | 995 | 0.380 |
Why?
|
Genes, myc | 10 | 2015 | 393 | 0.370 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1882 | 0.370 |
Why?
|
Computer Simulation | 1 | 2024 | 6255 | 0.370 |
Why?
|
Anemia, Sickle Cell | 4 | 2023 | 1067 | 0.360 |
Why?
|
Hodgkin Disease | 8 | 2014 | 1383 | 0.360 |
Why?
|
Bone Neoplasms | 6 | 2019 | 2567 | 0.350 |
Why?
|
Antineoplastic Agents | 20 | 2020 | 13648 | 0.350 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2024 | 330 | 0.340 |
Why?
|
Etoposide | 18 | 2018 | 636 | 0.330 |
Why?
|
3-Iodobenzylguanidine | 6 | 2023 | 113 | 0.320 |
Why?
|
Cisplatin | 17 | 2014 | 1658 | 0.320 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2017 | 639 | 0.320 |
Why?
|
Male | 120 | 2024 | 363698 | 0.310 |
Why?
|
Risk Assessment | 18 | 2024 | 24282 | 0.310 |
Why?
|
Mitotic Index | 3 | 2020 | 159 | 0.310 |
Why?
|
Antibodies, Monoclonal | 9 | 2021 | 9249 | 0.300 |
Why?
|
Models, Statistical | 3 | 2018 | 5089 | 0.300 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2008 | 121 | 0.290 |
Why?
|
Skin Neoplasms | 7 | 2023 | 5849 | 0.290 |
Why?
|
Stomatitis | 2 | 2023 | 270 | 0.290 |
Why?
|
Female | 119 | 2024 | 396112 | 0.280 |
Why?
|
Combined Modality Therapy | 22 | 2023 | 8529 | 0.280 |
Why?
|
Neoplasms | 13 | 2024 | 22340 | 0.280 |
Why?
|
Germinoma | 6 | 2006 | 124 | 0.280 |
Why?
|
Receptors, KIR | 3 | 2023 | 114 | 0.280 |
Why?
|
Infant, Newborn | 33 | 2024 | 26346 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 18 | 2016 | 6499 | 0.270 |
Why?
|
Cause of Death | 1 | 2017 | 3708 | 0.270 |
Why?
|
Risk Factors | 49 | 2024 | 74840 | 0.270 |
Why?
|
Glioma | 4 | 2024 | 3493 | 0.260 |
Why?
|
Retrospective Studies | 42 | 2024 | 81514 | 0.250 |
Why?
|
Genetic Association Studies | 5 | 2020 | 2741 | 0.250 |
Why?
|
Maximum Tolerated Dose | 3 | 2024 | 898 | 0.250 |
Why?
|
Brain Neoplasms | 8 | 2024 | 9071 | 0.250 |
Why?
|
Young Adult | 40 | 2024 | 59889 | 0.250 |
Why?
|
Chromosomes, Human, Pair 1 | 6 | 2013 | 640 | 0.250 |
Why?
|
Medical Oncology | 4 | 2024 | 2339 | 0.240 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2024 | 3655 | 0.240 |
Why?
|
Transplantation, Autologous | 10 | 2023 | 2120 | 0.240 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2024 | 878 | 0.230 |
Why?
|
Gene Expression Regulation, Neoplastic | 18 | 2020 | 8611 | 0.230 |
Why?
|
Mitosis | 3 | 2020 | 1173 | 0.230 |
Why?
|
Carcinoma, Basal Cell | 2 | 2020 | 566 | 0.230 |
Why?
|
Chromosomes, Human, Pair 6 | 3 | 2018 | 371 | 0.230 |
Why?
|
Osteosarcoma | 4 | 2018 | 909 | 0.220 |
Why?
|
Multidrug Resistance-Associated Proteins | 3 | 2011 | 105 | 0.210 |
Why?
|
Wiskott-Aldrich Syndrome | 1 | 2023 | 131 | 0.210 |
Why?
|
Loss of Heterozygosity | 7 | 2019 | 663 | 0.210 |
Why?
|
Stem Cell Transplantation | 8 | 2019 | 1602 | 0.200 |
Why?
|
Bleomycin | 11 | 2012 | 491 | 0.200 |
Why?
|
Ploidies | 6 | 2011 | 287 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2020 | 4044 | 0.200 |
Why?
|
Follow-Up Studies | 23 | 2024 | 39193 | 0.200 |
Why?
|
Chromosome Aberrations | 9 | 2022 | 1774 | 0.200 |
Why?
|
Carboplatin | 9 | 2018 | 789 | 0.200 |
Why?
|
Neoadjuvant Therapy | 6 | 2019 | 2895 | 0.200 |
Why?
|
Cohort Studies | 27 | 2021 | 41649 | 0.190 |
Why?
|
RNA Interference | 4 | 2020 | 2832 | 0.190 |
Why?
|
Whole-Body Irradiation | 3 | 2023 | 438 | 0.190 |
Why?
|
Hepatoblastoma | 3 | 2009 | 90 | 0.190 |
Why?
|
Adrenal Gland Neoplasms | 5 | 2016 | 730 | 0.190 |
Why?
|
Eczema | 1 | 2023 | 246 | 0.180 |
Why?
|
Medulloblastoma | 2 | 2023 | 658 | 0.180 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 5 | 2008 | 480 | 0.180 |
Why?
|
Myelodysplastic Syndromes | 3 | 2020 | 1404 | 0.180 |
Why?
|
Treatment Outcome | 39 | 2021 | 65188 | 0.170 |
Why?
|
Gene Dosage | 3 | 2017 | 1216 | 0.170 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2023 | 3646 | 0.170 |
Why?
|
gamma-Globins | 1 | 2020 | 105 | 0.170 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.170 |
Why?
|
Receptor, trkA | 3 | 2011 | 159 | 0.170 |
Why?
|
Peripheral Nervous System Neoplasms | 2 | 2014 | 134 | 0.170 |
Why?
|
Bone Marrow Transplantation | 4 | 2014 | 2729 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 2 | 2018 | 227 | 0.160 |
Why?
|
Recurrence | 8 | 2023 | 8501 | 0.160 |
Why?
|
Pilot Projects | 12 | 2023 | 8733 | 0.160 |
Why?
|
Research Subjects | 1 | 2021 | 247 | 0.160 |
Why?
|
Genomics | 6 | 2024 | 5929 | 0.160 |
Why?
|
Cerebellar Neoplasms | 1 | 2023 | 571 | 0.160 |
Why?
|
Cytomegalovirus Infections | 2 | 2016 | 836 | 0.160 |
Why?
|
Receptor Protein-Tyrosine Kinases | 5 | 2014 | 1624 | 0.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 4562 | 0.160 |
Why?
|
Proportional Hazards Models | 14 | 2021 | 12509 | 0.160 |
Why?
|
Data Interpretation, Statistical | 2 | 2024 | 2686 | 0.150 |
Why?
|
Salvage Therapy | 3 | 2014 | 1272 | 0.150 |
Why?
|
Disease Progression | 10 | 2019 | 13632 | 0.150 |
Why?
|
Sunburn | 1 | 2019 | 156 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2024 | 954 | 0.150 |
Why?
|
Polyamines | 1 | 2019 | 130 | 0.150 |
Why?
|
Gene Expression | 4 | 2014 | 7584 | 0.150 |
Why?
|
Mutation | 11 | 2024 | 30198 | 0.150 |
Why?
|
Amifostine | 2 | 2009 | 39 | 0.150 |
Why?
|
Opsoclonus-Myoclonus Syndrome | 1 | 2017 | 10 | 0.150 |
Why?
|
Fetal Hemoglobin | 1 | 2020 | 348 | 0.150 |
Why?
|
Cell Line, Tumor | 19 | 2019 | 17075 | 0.150 |
Why?
|
Chromosomes, Human, Pair 11 | 5 | 2013 | 412 | 0.140 |
Why?
|
Blood Component Removal | 1 | 2018 | 124 | 0.140 |
Why?
|
Radiation-Protective Agents | 2 | 2009 | 87 | 0.140 |
Why?
|
Sunlight | 1 | 2019 | 337 | 0.140 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 245 | 0.140 |
Why?
|
Adult | 46 | 2024 | 223044 | 0.140 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 245 | 0.140 |
Why?
|
Genotype | 10 | 2023 | 13024 | 0.140 |
Why?
|
Doxorubicin | 10 | 2018 | 2230 | 0.140 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2017 | 116 | 0.130 |
Why?
|
Iron Overload | 1 | 2018 | 245 | 0.130 |
Why?
|
Health Literacy | 1 | 2022 | 464 | 0.130 |
Why?
|
Neoplasm, Residual | 2 | 2020 | 1009 | 0.130 |
Why?
|
Anemia, Aplastic | 2 | 2015 | 232 | 0.130 |
Why?
|
Homeopathy | 1 | 1995 | 30 | 0.130 |
Why?
|
Survivors | 3 | 2016 | 2372 | 0.130 |
Why?
|
Vincristine | 8 | 2012 | 1039 | 0.120 |
Why?
|
Disabled Children | 1 | 2018 | 250 | 0.120 |
Why?
|
Pyrazoles | 3 | 2021 | 2033 | 0.120 |
Why?
|
Immunotherapy | 5 | 2023 | 4752 | 0.120 |
Why?
|
RNA, Small Interfering | 5 | 2020 | 3421 | 0.120 |
Why?
|
Lymph Nodes | 2 | 2019 | 3454 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 2 | 2011 | 1061 | 0.120 |
Why?
|
Age of Onset | 3 | 2015 | 3344 | 0.120 |
Why?
|
Dermatitis, Phototoxic | 1 | 2014 | 17 | 0.120 |
Why?
|
Gammaretrovirus | 1 | 2014 | 24 | 0.120 |
Why?
|
Pediatrics | 4 | 2024 | 3606 | 0.120 |
Why?
|
DNA Helicases | 2 | 2012 | 852 | 0.120 |
Why?
|
X-Linked Combined Immunodeficiency Diseases | 1 | 2014 | 24 | 0.120 |
Why?
|
Poverty | 3 | 2015 | 2714 | 0.120 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2056 | 0.120 |
Why?
|
Nevus, Pigmented | 1 | 2017 | 227 | 0.120 |
Why?
|
Microtubule-Associated Proteins | 2 | 2012 | 1066 | 0.120 |
Why?
|
Remission Induction | 10 | 2014 | 2411 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2014 | 16047 | 0.120 |
Why?
|
Hearing Loss | 2 | 2014 | 784 | 0.120 |
Why?
|
Research Design | 3 | 2024 | 6209 | 0.110 |
Why?
|
School Health Services | 1 | 2018 | 387 | 0.110 |
Why?
|
Prednisone | 2 | 2017 | 1565 | 0.110 |
Why?
|
Ependymoma | 1 | 2017 | 310 | 0.110 |
Why?
|
Histone Deacetylase 2 | 1 | 2014 | 71 | 0.110 |
Why?
|
Uterine Hemorrhage | 1 | 2015 | 235 | 0.110 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2014 | 86 | 0.110 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2018 | 374 | 0.110 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1385 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2019 | 769 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 5337 | 0.110 |
Why?
|
Testicular Neoplasms | 3 | 2004 | 786 | 0.110 |
Why?
|
Iodine Radioisotopes | 3 | 2013 | 1029 | 0.110 |
Why?
|
Melanoma | 2 | 2023 | 5719 | 0.110 |
Why?
|
Immunomagnetic Separation | 1 | 2013 | 78 | 0.110 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2011 | 70 | 0.110 |
Why?
|
Transplantation Conditioning | 3 | 2023 | 1635 | 0.110 |
Why?
|
Thoracic Neoplasms | 2 | 2014 | 267 | 0.110 |
Why?
|
Tubulin Modulators | 1 | 2013 | 107 | 0.110 |
Why?
|
Consensus | 3 | 2018 | 3202 | 0.100 |
Why?
|
Spinal Cord Compression | 2 | 2024 | 234 | 0.100 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2017 | 669 | 0.100 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4850 | 0.100 |
Why?
|
Serine Endopeptidases | 1 | 2018 | 1024 | 0.100 |
Why?
|
Physician Executives | 1 | 2014 | 140 | 0.100 |
Why?
|
Neurofibromatosis 1 | 1 | 2018 | 560 | 0.100 |
Why?
|
Iron | 2 | 2018 | 1816 | 0.100 |
Why?
|
Cell Nucleolus | 1 | 2013 | 155 | 0.100 |
Why?
|
Research Report | 2 | 2013 | 367 | 0.100 |
Why?
|
RNA, Messenger | 10 | 2012 | 12768 | 0.100 |
Why?
|
Diabetes Insipidus | 1 | 2013 | 143 | 0.100 |
Why?
|
DNA-Binding Proteins | 4 | 2016 | 9601 | 0.100 |
Why?
|
Karyotyping | 1 | 2014 | 1178 | 0.100 |
Why?
|
Neoplasm Metastasis | 9 | 2017 | 4893 | 0.100 |
Why?
|
Pelvic Neoplasms | 1 | 2014 | 247 | 0.100 |
Why?
|
Nervous System Neoplasms | 2 | 2009 | 91 | 0.100 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2010 | 0.100 |
Why?
|
Prospective Studies | 16 | 2024 | 54802 | 0.100 |
Why?
|
Immunohistochemistry | 6 | 2021 | 11022 | 0.100 |
Why?
|
Amenorrhea | 1 | 2015 | 470 | 0.100 |
Why?
|
Pituitary Diseases | 1 | 2013 | 136 | 0.100 |
Why?
|
Fenretinide | 1 | 2011 | 9 | 0.100 |
Why?
|
Thymopentin | 1 | 2011 | 1 | 0.100 |
Why?
|
Receptor, Nerve Growth Factor | 1 | 2011 | 48 | 0.100 |
Why?
|
Receptors, Interleukin-6 | 2 | 2012 | 226 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 2453 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10383 | 0.090 |
Why?
|
Glutathione S-Transferase pi | 1 | 2011 | 99 | 0.090 |
Why?
|
Razoxane | 2 | 2012 | 43 | 0.090 |
Why?
|
Gene Expression Profiling | 7 | 2016 | 9525 | 0.090 |
Why?
|
Medical Records | 2 | 2015 | 1409 | 0.090 |
Why?
|
Radiopharmaceuticals | 4 | 2017 | 2699 | 0.090 |
Why?
|
Fever | 2 | 2017 | 1603 | 0.090 |
Why?
|
Camptothecin | 3 | 2017 | 600 | 0.090 |
Why?
|
Neonatal Screening | 1 | 2016 | 627 | 0.090 |
Why?
|
Telomerase | 1 | 2016 | 749 | 0.090 |
Why?
|
Erythrocytes | 1 | 2020 | 2395 | 0.090 |
Why?
|
Oncogenes | 3 | 2014 | 1235 | 0.090 |
Why?
|
Gene Silencing | 3 | 2014 | 1505 | 0.090 |
Why?
|
Time Factors | 14 | 2019 | 40065 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 12 | 2020 | 18071 | 0.090 |
Why?
|
Predictive Value of Tests | 12 | 2015 | 15398 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 2 | 2023 | 3401 | 0.090 |
Why?
|
MicroRNAs | 3 | 2011 | 3785 | 0.090 |
Why?
|
Pituitary Gland | 1 | 2013 | 631 | 0.090 |
Why?
|
Risk | 7 | 2019 | 9591 | 0.090 |
Why?
|
Gangliosides | 1 | 2010 | 132 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2020 | 2968 | 0.080 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2015 | 1133 | 0.080 |
Why?
|
Income | 2 | 2015 | 1874 | 0.080 |
Why?
|
Caspase 8 | 2 | 2007 | 198 | 0.080 |
Why?
|
DNA Copy Number Variations | 3 | 2018 | 2045 | 0.080 |
Why?
|
Genetic Vectors | 2 | 2020 | 3404 | 0.080 |
Why?
|
Skin Diseases | 1 | 2018 | 1088 | 0.080 |
Why?
|
Fanconi Anemia | 1 | 2012 | 327 | 0.080 |
Why?
|
Craniopharyngioma | 1 | 2012 | 276 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2003 | 0.080 |
Why?
|
Transcription Factors | 3 | 2016 | 12131 | 0.080 |
Why?
|
Ornithine Decarboxylase | 1 | 2008 | 63 | 0.080 |
Why?
|
Intention to Treat Analysis | 3 | 2019 | 416 | 0.080 |
Why?
|
Anticoagulants | 1 | 2024 | 4862 | 0.080 |
Why?
|
Diarrhea | 1 | 1995 | 1316 | 0.080 |
Why?
|
Nerve Growth Factors | 1 | 2011 | 565 | 0.080 |
Why?
|
Ribonuclease III | 1 | 2010 | 269 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2016 | 2942 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 493 | 0.070 |
Why?
|
Causality | 2 | 2014 | 1248 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 2017 | 1165 | 0.070 |
Why?
|
Gene Deletion | 3 | 2013 | 2666 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 2 | 2009 | 2796 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 1808 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2650 | 0.070 |
Why?
|
Tumor Necrosis Factor Decoy Receptors | 1 | 2007 | 8 | 0.070 |
Why?
|
Age Distribution | 2 | 2010 | 2858 | 0.070 |
Why?
|
Nerve Tissue Proteins | 2 | 2012 | 4392 | 0.070 |
Why?
|
Abdominal Neoplasms | 3 | 2005 | 284 | 0.070 |
Why?
|
Receptors, IgG | 1 | 2010 | 559 | 0.070 |
Why?
|
Multivariate Analysis | 7 | 2019 | 12056 | 0.070 |
Why?
|
North America | 1 | 2010 | 1285 | 0.070 |
Why?
|
Europe | 2 | 2010 | 3423 | 0.070 |
Why?
|
Australia | 1 | 2010 | 1258 | 0.070 |
Why?
|
Transfection | 5 | 2014 | 5743 | 0.070 |
Why?
|
Ligands | 3 | 2023 | 3273 | 0.070 |
Why?
|
Spinal Neoplasms | 2 | 2024 | 708 | 0.070 |
Why?
|
Preoperative Care | 1 | 2015 | 2267 | 0.070 |
Why?
|
Japan | 1 | 2010 | 1415 | 0.070 |
Why?
|
Genetic Variation | 3 | 2014 | 6610 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4209 | 0.060 |
Why?
|
Transplantation, Homologous | 4 | 2022 | 4860 | 0.060 |
Why?
|
Membrane Proteins | 3 | 2018 | 7851 | 0.060 |
Why?
|
DNA, Neoplasm | 2 | 2009 | 1742 | 0.060 |
Why?
|
Ovarian Neoplasms | 4 | 2016 | 4900 | 0.060 |
Why?
|
Ifosfamide | 3 | 2014 | 233 | 0.060 |
Why?
|
Polymerase Chain Reaction | 6 | 2016 | 6069 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3797 | 0.060 |
Why?
|
Chelating Agents | 1 | 2007 | 380 | 0.060 |
Why?
|
Hearing Disorders | 1 | 2005 | 126 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3615 | 0.060 |
Why?
|
Bone Marrow | 1 | 2015 | 2921 | 0.060 |
Why?
|
Radionuclide Imaging | 3 | 2015 | 1978 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 3430 | 0.060 |
Why?
|
Hospitalization | 1 | 2024 | 10808 | 0.060 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2006 | 616 | 0.060 |
Why?
|
Pandemics | 1 | 2024 | 8703 | 0.060 |
Why?
|
Methylation | 1 | 2007 | 1073 | 0.060 |
Why?
|
Genome-Wide Association Study | 3 | 2014 | 12807 | 0.060 |
Why?
|
Parents | 1 | 2018 | 3592 | 0.060 |
Why?
|
United States | 9 | 2019 | 72903 | 0.060 |
Why?
|
Sulfonamides | 1 | 2013 | 1984 | 0.060 |
Why?
|
Terminal Care | 1 | 2016 | 1774 | 0.060 |
Why?
|
Leukemia, Myeloid | 1 | 2007 | 696 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3925 | 0.050 |
Why?
|
Probability | 2 | 2007 | 2475 | 0.050 |
Why?
|
Cell Differentiation | 4 | 2015 | 11641 | 0.050 |
Why?
|
Italy | 1 | 2005 | 854 | 0.050 |
Why?
|
Germany | 1 | 2005 | 882 | 0.050 |
Why?
|
Incidence | 7 | 2016 | 21480 | 0.050 |
Why?
|
Diploidy | 3 | 2008 | 141 | 0.050 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8041 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5696 | 0.050 |
Why?
|
Head and Neck Neoplasms | 3 | 2014 | 2921 | 0.050 |
Why?
|
Down-Regulation | 3 | 2020 | 2927 | 0.050 |
Why?
|
Wiskott-Aldrich Syndrome Protein | 1 | 2023 | 163 | 0.050 |
Why?
|
Cell Cycle | 2 | 2020 | 2920 | 0.050 |
Why?
|
Logistic Models | 5 | 2019 | 13266 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 36532 | 0.050 |
Why?
|
Blotting, Western | 5 | 2015 | 5020 | 0.050 |
Why?
|
Central Nervous System Neoplasms | 1 | 2011 | 916 | 0.050 |
Why?
|
Pyridines | 1 | 2014 | 2888 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1927 | 0.050 |
Why?
|
Hematopoiesis | 1 | 2012 | 2058 | 0.050 |
Why?
|
International Cooperation | 3 | 2015 | 1432 | 0.050 |
Why?
|
Spinal Cord Neoplasms | 1 | 2024 | 258 | 0.050 |
Why?
|
Developing Countries | 1 | 2015 | 2911 | 0.050 |
Why?
|
Capsules | 2 | 2013 | 193 | 0.050 |
Why?
|
Liver Neoplasms | 3 | 2016 | 4353 | 0.050 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2005 | 296 | 0.050 |
Why?
|
Urogenital Neoplasms | 1 | 2003 | 129 | 0.050 |
Why?
|
New England | 2 | 2015 | 1059 | 0.050 |
Why?
|
Decontamination | 1 | 2022 | 73 | 0.050 |
Why?
|
Sequence Analysis, DNA | 4 | 2018 | 4772 | 0.050 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2001 | 84 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2014 | 2418 | 0.050 |
Why?
|
Histocompatibility Antigens | 1 | 2023 | 477 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6493 | 0.050 |
Why?
|
Cross-Sectional Studies | 6 | 2019 | 26318 | 0.050 |
Why?
|
Blood Transfusion | 2 | 2018 | 1297 | 0.050 |
Why?
|
Dacarbazine | 2 | 2017 | 552 | 0.050 |
Why?
|
Radiotherapy | 3 | 2019 | 1494 | 0.050 |
Why?
|
Sarcoma | 1 | 2012 | 1802 | 0.050 |
Why?
|
Paclitaxel | 2 | 2008 | 1728 | 0.050 |
Why?
|
Length of Stay | 1 | 2015 | 6485 | 0.050 |
Why?
|
Neutropenia | 3 | 2017 | 893 | 0.040 |
Why?
|
Orchiectomy | 1 | 2003 | 460 | 0.040 |
Why?
|
Palliative Care | 1 | 2016 | 3645 | 0.040 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 1560 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6547 | 0.040 |
Why?
|
Patient Readmission | 1 | 2015 | 3286 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1628 | 0.040 |
Why?
|
Busulfan | 1 | 2021 | 264 | 0.040 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2012 | 1883 | 0.040 |
Why?
|
Benzoates | 1 | 2021 | 213 | 0.040 |
Why?
|
Case-Control Studies | 5 | 2020 | 22223 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2012 | 2505 | 0.040 |
Why?
|
Hydrazines | 1 | 2021 | 223 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 2844 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2009 | 1892 | 0.040 |
Why?
|
GATA2 Transcription Factor | 1 | 2020 | 158 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 574 | 0.040 |
Why?
|
Vinblastine | 2 | 2014 | 483 | 0.040 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2003 | 335 | 0.040 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2012 | 416 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2008 | 2423 | 0.040 |
Why?
|
Melphalan | 1 | 2021 | 425 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2009 | 3222 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13451 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 728 | 0.040 |
Why?
|
Colony-Forming Units Assay | 2 | 2010 | 351 | 0.040 |
Why?
|
Pyrimidines | 1 | 2011 | 3047 | 0.040 |
Why?
|
Mice | 10 | 2022 | 81819 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2010 | 1880 | 0.040 |
Why?
|
Hepatomegaly | 1 | 2018 | 83 | 0.040 |
Why?
|
Odds Ratio | 4 | 2012 | 9649 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 14071 | 0.040 |
Why?
|
Filgrastim | 1 | 2018 | 131 | 0.040 |
Why?
|
Platelet Count | 1 | 2021 | 782 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 869 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2008 | 2844 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 703 | 0.040 |
Why?
|
Radiometry | 1 | 2023 | 804 | 0.040 |
Why?
|
Up-Regulation | 3 | 2014 | 4137 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2023 | 1238 | 0.040 |
Why?
|
Life Tables | 3 | 2004 | 363 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2018 | 3586 | 0.040 |
Why?
|
Animals | 14 | 2022 | 168764 | 0.040 |
Why?
|
Receptors, KIR2DL1 | 1 | 2017 | 13 | 0.040 |
Why?
|
Biosynthetic Pathways | 1 | 2019 | 138 | 0.040 |
Why?
|
DNA Methylation | 2 | 2012 | 4424 | 0.040 |
Why?
|
Receptors, KIR3DL1 | 1 | 2017 | 27 | 0.040 |
Why?
|
Urinary Catheterization | 1 | 1999 | 195 | 0.040 |
Why?
|
Mediastinal Neoplasms | 1 | 2001 | 403 | 0.040 |
Why?
|
Nail Diseases | 1 | 2018 | 54 | 0.040 |
Why?
|
Illinois | 1 | 2017 | 120 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 251 | 0.040 |
Why?
|
Treatment Failure | 2 | 2014 | 2652 | 0.040 |
Why?
|
Macrophages | 1 | 2012 | 5772 | 0.040 |
Why?
|
Cell Proliferation | 4 | 2016 | 10429 | 0.040 |
Why?
|
Neoplasm Invasiveness | 1 | 2005 | 3602 | 0.030 |
Why?
|
DNA, Complementary | 2 | 2014 | 1984 | 0.030 |
Why?
|
Middle Aged | 13 | 2024 | 223009 | 0.030 |
Why?
|
Washington | 1 | 2017 | 314 | 0.030 |
Why?
|
Defibrillators, Implantable | 2 | 1998 | 1490 | 0.030 |
Why?
|
Prevalence | 3 | 2021 | 15842 | 0.030 |
Why?
|
Vitiligo | 1 | 2018 | 96 | 0.030 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 553 | 0.030 |
Why?
|
Cell Movement | 3 | 2016 | 5194 | 0.030 |
Why?
|
Urinary Incontinence, Stress | 1 | 1999 | 180 | 0.030 |
Why?
|
Genome, Human | 4 | 2013 | 4448 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2017 | 1776 | 0.030 |
Why?
|
Urethra | 1 | 1999 | 406 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2019 | 5302 | 0.030 |
Why?
|
alpha-Fetoproteins | 2 | 2008 | 226 | 0.030 |
Why?
|
Quality of Life | 4 | 2021 | 13462 | 0.030 |
Why?
|
Genetic Markers | 3 | 2009 | 2601 | 0.030 |
Why?
|
Splenectomy | 1 | 2018 | 390 | 0.030 |
Why?
|
Isoelectric Focusing | 1 | 2016 | 148 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1599 | 0.030 |
Why?
|
Hypokalemia | 1 | 2017 | 154 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1857 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 647 | 0.030 |
Why?
|
Mice, Nude | 2 | 2015 | 3618 | 0.030 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 4108 | 0.030 |
Why?
|
Cholecystectomy | 1 | 2018 | 407 | 0.030 |
Why?
|
Animals, Genetically Modified | 1 | 2020 | 1560 | 0.030 |
Why?
|
Myeloablative Agonists | 1 | 2016 | 215 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 598 | 0.030 |
Why?
|
Liberia | 1 | 2016 | 176 | 0.030 |
Why?
|
Premedication | 1 | 2016 | 244 | 0.030 |
Why?
|
Fluorouracil | 3 | 2006 | 1648 | 0.030 |
Why?
|
Ataxia | 1 | 2017 | 307 | 0.030 |
Why?
|
Goserelin | 1 | 2015 | 126 | 0.030 |
Why?
|
Apoptosis | 3 | 2020 | 9514 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2014 | 2721 | 0.030 |
Why?
|
Vaginal Smears | 1 | 1997 | 513 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2014 | 89 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 426 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2017 | 912 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2017 | 607 | 0.030 |
Why?
|
Contraceptive Agents, Female | 1 | 2015 | 123 | 0.030 |
Why?
|
Hydrogen Bonding | 1 | 2014 | 293 | 0.030 |
Why?
|
Cyclohexylamines | 1 | 2014 | 21 | 0.030 |
Why?
|
Suspensions | 1 | 2013 | 66 | 0.030 |
Why?
|
Gene Frequency | 2 | 2012 | 3624 | 0.030 |
Why?
|
Mice, Transgenic | 3 | 2011 | 9550 | 0.030 |
Why?
|
Transplantation, Heterologous | 2 | 2015 | 2394 | 0.030 |
Why?
|
Alleles | 3 | 2010 | 6897 | 0.030 |
Why?
|
Leuprolide | 1 | 2015 | 312 | 0.030 |
Why?
|
Internship and Residency | 1 | 2014 | 5946 | 0.030 |
Why?
|
Resuscitation Orders | 1 | 2016 | 275 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2018 | 1866 | 0.030 |
Why?
|
Alopecia | 1 | 2018 | 414 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2022 | 1217 | 0.030 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2016 | 316 | 0.030 |
Why?
|
Carcinoma | 1 | 2005 | 2312 | 0.030 |
Why?
|
Hepatitis Antibodies | 1 | 1993 | 67 | 0.030 |
Why?
|
Obesity | 2 | 2012 | 13076 | 0.030 |
Why?
|
Membrane Transport Proteins | 1 | 2019 | 1028 | 0.030 |
Why?
|
Radiography | 2 | 2015 | 6919 | 0.030 |
Why?
|
Viremia | 1 | 2016 | 727 | 0.030 |
Why?
|
International Classification of Diseases | 2 | 2008 | 935 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 240 | 0.030 |
Why?
|
Histones | 1 | 2023 | 2584 | 0.030 |
Why?
|
Ribosomes | 1 | 2016 | 493 | 0.030 |
Why?
|
Central America | 1 | 2012 | 69 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 2014 | 234 | 0.030 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2016 | 488 | 0.020 |
Why?
|
Hepatitis E virus | 1 | 1993 | 72 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2014 | 656 | 0.020 |
Why?
|
Phenotype | 3 | 2018 | 16721 | 0.020 |
Why?
|
Hepatitis E | 1 | 1993 | 76 | 0.020 |
Why?
|
Carcinoma in Situ | 1 | 1997 | 779 | 0.020 |
Why?
|
Cytokines | 1 | 2007 | 7421 | 0.020 |
Why?
|
Second-Look Surgery | 1 | 2011 | 27 | 0.020 |
Why?
|
SEER Program | 1 | 2017 | 1446 | 0.020 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 1 | 2012 | 51 | 0.020 |
Why?
|
Receptor, trkB | 1 | 2012 | 122 | 0.020 |
Why?
|
Reproducibility of Results | 5 | 2011 | 20124 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2020 | 1944 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2014 | 898 | 0.020 |
Why?
|
Boston | 2 | 2014 | 9338 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1884 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 389 | 0.020 |
Why?
|
Transgenes | 1 | 2014 | 1015 | 0.020 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 281 | 0.020 |
Why?
|
Quality Control | 1 | 2014 | 837 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10729 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15880 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3211 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2016 | 1441 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2009 | 2865 | 0.020 |
Why?
|
Receptors, Eph Family | 2 | 2000 | 44 | 0.020 |
Why?
|
Receptor, EphB4 | 2 | 2000 | 39 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 721 | 0.020 |
Why?
|
Retinoids | 1 | 2011 | 98 | 0.020 |
Why?
|
Adrenalectomy | 1 | 2012 | 344 | 0.020 |
Why?
|
Ephrin-B3 | 2 | 2000 | 12 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1701 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
Drug Resistance, Multiple | 1 | 2011 | 255 | 0.020 |
Why?
|
Ephrin-B2 | 2 | 2000 | 40 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 614 | 0.020 |
Why?
|
Sirolimus | 1 | 2017 | 1545 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 919 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2013 | 500 | 0.020 |
Why?
|
Leukemia Virus, Murine | 1 | 1990 | 96 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2012 | 3537 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 932 | 0.020 |
Why?
|
Rhabdomyosarcoma | 1 | 2012 | 354 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2014 | 641 | 0.020 |
Why?
|
Gene Duplication | 1 | 2010 | 317 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1885 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2014 | 866 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2017 | 1171 | 0.020 |
Why?
|
Biogenic Polyamines | 1 | 2008 | 4 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2334 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 329 | 0.020 |
Why?
|
Eflornithine | 1 | 2008 | 31 | 0.020 |
Why?
|
Receptors, Interleukin-2 | 1 | 2010 | 561 | 0.020 |
Why?
|
Bone Marrow Purging | 1 | 2009 | 108 | 0.020 |
Why?
|
Zebrafish | 1 | 2020 | 3036 | 0.020 |
Why?
|
Chromosome Breakage | 1 | 2009 | 159 | 0.020 |
Why?
|
DNA, Antisense | 1 | 2008 | 44 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2016 | 18973 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2017 | 2024 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2010 | 790 | 0.020 |
Why?
|
Prednisolone | 1 | 2009 | 324 | 0.020 |
Why?
|
Mass Screening | 2 | 2021 | 5446 | 0.020 |
Why?
|
Phosphorylation | 2 | 2014 | 8278 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3432 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1509 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2009 | 1306 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2260 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2008 | 381 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2014 | 999 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2010 | 745 | 0.020 |
Why?
|
Disease Management | 1 | 2018 | 2535 | 0.020 |
Why?
|
Calcium-Binding Proteins | 1 | 2012 | 1077 | 0.020 |
Why?
|
Anemia | 1 | 2017 | 1511 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2009 | 5786 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2008 | 610 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2012 | 1495 | 0.020 |
Why?
|
DNA Repair | 1 | 2016 | 2048 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2006 | 6203 | 0.020 |
Why?
|
Comparative Genomic Hybridization | 1 | 2008 | 476 | 0.020 |
Why?
|
Biopsy | 2 | 2014 | 6763 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5876 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2012 | 1130 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2009 | 14652 | 0.020 |
Why?
|
Kinetics | 1 | 2014 | 6274 | 0.020 |
Why?
|
Virus Diseases | 1 | 2013 | 718 | 0.020 |
Why?
|
Sympathetic Nervous System | 1 | 2009 | 520 | 0.020 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2007 | 94 | 0.020 |
Why?
|
Skin | 1 | 2020 | 4489 | 0.020 |
Why?
|
Azacitidine | 1 | 2008 | 334 | 0.020 |
Why?
|
Procarbazine | 1 | 2006 | 172 | 0.020 |
Why?
|
Mechlorethamine | 1 | 2006 | 129 | 0.020 |
Why?
|
Cost of Illness | 1 | 2016 | 1950 | 0.020 |
Why?
|
Genes, MDR | 1 | 2006 | 36 | 0.020 |
Why?
|
Laboratories | 1 | 2010 | 462 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18293 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2014 | 2887 | 0.020 |
Why?
|
Tachycardia, Ventricular | 1 | 1995 | 1310 | 0.020 |
Why?
|
DNA Primers | 1 | 2010 | 2825 | 0.020 |
Why?
|
Signal Transduction | 3 | 2020 | 23601 | 0.020 |
Why?
|
Chorionic Gonadotropin | 1 | 2008 | 457 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2010 | 1167 | 0.020 |
Why?
|
Social Support | 1 | 2015 | 2192 | 0.020 |
Why?
|
Program Evaluation | 1 | 2014 | 2499 | 0.020 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2006 | 202 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 1997 | 2047 | 0.020 |
Why?
|
Enzyme Inhibitors | 2 | 2007 | 3715 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1287 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2014 | 2589 | 0.020 |
Why?
|
Plasmids | 1 | 2010 | 2274 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2013 | 1203 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1859 | 0.010 |
Why?
|
HLA Antigens | 1 | 2010 | 1339 | 0.010 |
Why?
|
Antibodies | 1 | 2013 | 2417 | 0.010 |
Why?
|
Hospitals, Pediatric | 1 | 2014 | 1846 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8875 | 0.010 |
Why?
|
Hospitals | 1 | 2018 | 3888 | 0.010 |
Why?
|
Models, Molecular | 1 | 2014 | 5379 | 0.010 |
Why?
|
Drug Synergism | 1 | 2008 | 1749 | 0.010 |
Why?
|
Diagnostic Imaging | 2 | 2011 | 3529 | 0.010 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2008 | 647 | 0.010 |
Why?
|
Research | 1 | 2012 | 1975 | 0.010 |
Why?
|
Fibroblasts | 2 | 2012 | 4159 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2011 | 3089 | 0.010 |
Why?
|
Aged | 6 | 2024 | 171117 | 0.010 |
Why?
|
Cytarabine | 1 | 2006 | 698 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2016 | 3050 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2009 | 906 | 0.010 |
Why?
|
Administration, Oral | 1 | 2011 | 4015 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 633 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 1995 | 2592 | 0.010 |
Why?
|
Homozygote | 1 | 2008 | 1775 | 0.010 |
Why?
|
Caspases | 1 | 2006 | 880 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 2013 | 1660 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2012 | 2817 | 0.010 |
Why?
|
Leucovorin | 1 | 2005 | 641 | 0.010 |
Why?
|
Trans-Activators | 1 | 2012 | 2850 | 0.010 |
Why?
|
Gene Targeting | 1 | 2006 | 841 | 0.010 |
Why?
|
Vaginal Neoplasms | 1 | 2003 | 104 | 0.010 |
Why?
|
Protein Binding | 1 | 2014 | 9296 | 0.010 |
Why?
|
Heterozygote | 1 | 2009 | 2794 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2692 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 679 | 0.010 |
Why?
|
Pain | 1 | 2017 | 5077 | 0.010 |
Why?
|
DNA Damage | 1 | 2012 | 2457 | 0.010 |
Why?
|
Decision Making | 1 | 2016 | 3965 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2009 | 2086 | 0.010 |
Why?
|
Antigens, CD | 1 | 2012 | 4025 | 0.010 |
Why?
|
Cyclin D | 1 | 2001 | 70 | 0.010 |
Why?
|
Fetus | 1 | 2009 | 1870 | 0.010 |
Why?
|
Immunoblotting | 1 | 2005 | 1644 | 0.010 |
Why?
|
Penile Neoplasms | 1 | 2003 | 156 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2008 | 3750 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2010 | 2210 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2015 | 7838 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2019 | 11888 | 0.010 |
Why?
|
Biological Transport | 1 | 2005 | 2081 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6309 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2008 | 1352 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4247 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10563 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4255 | 0.010 |
Why?
|
Laminectomy | 1 | 2001 | 226 | 0.010 |
Why?
|
Paresis | 1 | 2001 | 176 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2001 | 360 | 0.010 |
Why?
|
Cyclins | 1 | 2001 | 598 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2005 | 1078 | 0.010 |
Why?
|
Regression Analysis | 1 | 2008 | 6322 | 0.010 |
Why?
|
Cell Survival | 1 | 2008 | 5747 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2001 | 352 | 0.010 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2005 | 617 | 0.010 |
Why?
|
Differential Threshold | 1 | 1998 | 80 | 0.010 |
Why?
|
Clinical Competence | 1 | 2014 | 4863 | 0.010 |
Why?
|
Methotrexate | 1 | 2005 | 1722 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 2001 | 666 | 0.010 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2001 | 660 | 0.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2001 | 561 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2006 | 2867 | 0.010 |
Why?
|
Antigens, Viral | 2 | 1993 | 995 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2005 | 6113 | 0.010 |
Why?
|
Fiber Optic Technology | 1 | 1999 | 284 | 0.010 |
Why?
|
Urodynamics | 1 | 1999 | 349 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10261 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 20659 | 0.010 |
Why?
|
Lung Diseases | 1 | 2007 | 1940 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2012 | 14448 | 0.010 |
Why?
|
Cell Line | 2 | 2005 | 15543 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8297 | 0.010 |
Why?
|
Acute Disease | 1 | 2007 | 7232 | 0.010 |
Why?
|
Pressure | 1 | 1999 | 1168 | 0.010 |
Why?
|
Organ Specificity | 1 | 2000 | 1965 | 0.010 |
Why?
|
Automation | 1 | 1997 | 585 | 0.010 |
Why?
|
Electric Countershock | 1 | 1998 | 534 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2001 | 712 | 0.010 |
Why?
|
Fetal Diseases | 1 | 2000 | 914 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2003 | 1421 | 0.010 |
Why?
|
Heart Diseases | 1 | 2007 | 2821 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2007 | 3819 | 0.010 |
Why?
|
Moths | 1 | 1993 | 80 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 22332 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 2007 | 2371 | 0.010 |
Why?
|
Inflammation | 1 | 2012 | 10850 | 0.010 |
Why?
|
Ultrasonography, Prenatal | 1 | 2000 | 1774 | 0.010 |
Why?
|
Primates | 1 | 1993 | 518 | 0.010 |
Why?
|
Anti-Arrhythmia Agents | 1 | 1995 | 769 | 0.010 |
Why?
|
Base Sequence | 2 | 1993 | 12403 | 0.010 |
Why?
|
AIDS-Related Complex | 1 | 1990 | 107 | 0.010 |
Why?
|
Open Reading Frames | 1 | 1993 | 820 | 0.010 |
Why?
|
RNA | 1 | 1999 | 2717 | 0.000 |
Why?
|
Proto-Oncogene Proteins | 1 | 2001 | 4520 | 0.000 |
Why?
|
Precipitin Tests | 1 | 1990 | 812 | 0.000 |
Why?
|
Forecasting | 1 | 1998 | 2936 | 0.000 |
Why?
|
Molecular Sequence Data | 2 | 1993 | 17594 | 0.000 |
Why?
|
Cloning, Molecular | 1 | 1993 | 4165 | 0.000 |
Why?
|
Injections, Intravenous | 1 | 1990 | 1377 | 0.000 |
Why?
|
DNA, Viral | 1 | 1993 | 2199 | 0.000 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1993 | 3807 | 0.000 |
Why?
|
Muscular Dystrophy, Oculopharyngeal | 1 | 1963 | 9 | 0.000 |
Why?
|
Macaca mulatta | 1 | 1990 | 2341 | 0.000 |
Why?
|
Aged, 80 and over | 2 | 1999 | 59489 | 0.000 |
Why?
|
Virus Replication | 1 | 1990 | 2447 | 0.000 |
Why?
|
Eyelids | 1 | 1963 | 279 | 0.000 |
Why?
|
Muscular Dystrophies | 1 | 1963 | 392 | 0.000 |
Why?
|
Deglutition Disorders | 1 | 1963 | 639 | 0.000 |
Why?
|